Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2 -Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial

医学 肿瘤科 乳腺癌 内科学 随机对照试验 环磷酰胺 新辅助治疗 化疗 免疫检查点 临床试验 相伴的 紫杉醇 化学免疫疗法 激素疗法 随机化 癌症 放射治疗 易普利姆玛 封锁
作者
Claudine J. Isaacs,Rita Nanda,Christina S. F. Yau,Amy Jo Chien,Dawn L. Hershman,Erica Michelle Stringer-Reasor,Anne M. Wallace,Alexandra Thomas,Christos Vaklavas,Amy Sanders Clark,Laura Carpin Kennedy,Amy Sanford,Judy C. Boughey,Kathy S. Albain,Lajos Pusztai,Kevin M. Kalinsky,Heather Christine Beckwith,Nicole O. Williams,Hyo Sook Han,Carla Isadora Falkson
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:12 (9): 1008-1008 被引量:2
标识
DOI:10.1001/jamaoncol.2026.2576
摘要

Importance: Although adding immune checkpoint inhibitors to neoadjuvant chemotherapy improves outcomes in high-risk early-stage breast cancer, opportunities remain to further enhance response. Dual checkpoint blockade offers a potential strategy to further enhance efficacy. Objective: To evaluate the combination of anti-programmed cell death 1 protein (PD-1) cemiplimab and anti-lymphocyte activation gene 3 (LAG-3) added to neoadjuvant therapy in ERBB2-negative early-stage, high-risk breast cancer. Design, Setting, and Participants: The I-SPY2 (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2) is an ongoing randomized clinical platform trial being conducted at multiple US clinical sites including patients with early-stage (II or III) ERBB2-negative, high-risk breast cancer. Participants, continuously enrolled since 2010, were adaptively randomized from February 2, 2020, to December 9, 2021, to one of several experimental neoadjuvant therapies or control groups based on receptor subtypes defined by hormone receptor (HR), ERBB2 status, and MammaPrint (Agendia Inc) molecular risk, categorized as high (MP1) or ultrahigh (MP2). Data were analyzed from January 1, 2022, to August 5, 2025. Interventions: Both groups received weekly paclitaxel for 12 weeks, then doxorubicin and cyclophosphamide followed by surgery; concomitant with paclitaxel, the intervention group also received 4 doses of cemiplimab and fianlimab (PCF) every 3 weeks. Main Outcomes and Measures: Pathologic complete response (pCR). Treatments graduated when they achieved 85% bayesian probability of success in a subtype-specific phase 3 trial. Pathway-specific biomarkers were assessed for response prediction. Results: A total of 78 participants (mean [SD] age, 47 [39-54] years) were randomized to the intervention group, with 350 participants (mean [SD] age, 48 [39-57] years) randomized to the historical control population. PCF graduated in all clinical signatures, with pCR rates vs control of 44% (95% CI, 34%-53%) vs 21% (95% CI, 17%-25%) in all ERBB2, 53% (95% CI, 39%-67%) vs 29% (95% CI, 22%-36%) in triple-negative, and 36% (95% CI, 23%-49%) vs 14% (95% CI, 9%-19%) in HR-positive and ERBB2-negative disease. Among the total participants, 16 (21%) experienced adrenal insufficiency, including hypophysitis (11% grade 3 or 4), mostly occurring after immunotherapy completion. PCF was found to be highly effective in the subset of patients with immune signature positive status (ImPrint positive). Conclusions and Relevance: In this randomized clinical trial, the combination of PD-1 and anti-LAG-3 inhibition with standard NAC was effective in early-stage ERBB2-negative breast cancer, particularly in patients displaying a positive ImPrint immune signature. These results warrant further definitive trials. Trial Registration: ClinicalTrials.gov Identifier: NCT01042379.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LPY完成签到,获得积分10
1秒前
1秒前
1秒前
1秒前
ding的应助被111采纳,获得10
1秒前
毕夏之完成签到,获得积分10
1秒前
LiGanZe完成签到,获得积分10
1秒前
qq完成签到,获得积分10
1秒前
chentong0完成签到 ,获得积分10
2秒前
小马甲的应助被Mark_Y采纳,获得10
3秒前
希望天下0贩的0的应助被weeadas采纳,获得10
3秒前
3秒前
党参多糖发布了新的文献求助10
3秒前
阳光的衫完成签到,获得积分10
4秒前
风吹麦浪的应助被如意的沛芹采纳,获得10
4秒前
369ninja发布了新的文献求助10
5秒前
chen完成签到,获得积分10
5秒前
今后的应助被专注的绾绾采纳,获得30
5秒前
策力格尔完成签到,获得积分10
5秒前
5秒前
学术小白w完成签到,获得积分10
5秒前
高雅人士完成签到,获得积分10
5秒前
Vincent发布了新的文献求助10
5秒前
L_发布了新的文献求助10
6秒前
侯_完成签到,获得积分10
6秒前
6秒前
小亦雪发布了新的文献求助10
6秒前
6秒前
ZZZLJ完成签到,获得积分10
6秒前
刘雨凝完成签到,获得积分10
7秒前
7秒前
在水一方的应助被小羊采纳,获得10
7秒前
patrickzhao完成签到,获得积分10
7秒前
7秒前
8秒前
8秒前
8秒前
劉德助完成签到,获得积分10
9秒前
DW的应助被Cc采纳,获得10
9秒前
黎无道完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287